57 results about "In stent restenosis" patented technology

A catheter and catheter system can use energy tailored for remodeling and / or removal of target material proximate to a body lumen, often of stenotic material or tissue in the luminal wall of a blood vessel of a patient. An elongate flexible catheter body with a radially expandable structure may have a plurality of electrodes or other electrosurgical energy delivery surfaces to radially engage the luminal wall when the structure expands. Feedback using one or parameters of voltage, current, power, temperature, impedance magnitude, impedance phase angle, and frequency may be used to selectively control the delivery of energy.

A second stent having a wall thickness of 0.002 inches or less or a second stent having a tubular surface with openings therethrough where the ratio of the area of the surface to the area of the openings is at least 3:10 may be implanted in a first stent which has been previously implanted in a bodily vessel.

Pharmacologically active, easy-to-deploy, biomechanically compatible, inflatable endovascular, drug-eluting stent are formed of a primary expandable polymeric or metallic construct, intimately mantled with a biomechanically compatible, polymeric microporous, microfibrous, compliant, stretchable fabric formed by direct electrospinning onto the outside surface of the primary construct using at least one polymer solution containing at least one active compound, selected from those expected to control key biological events leading to in-stent restenosis.

The invention relates to a method for manufacturing a biodegradable shape-memory polymer intravascular stent additive with a negative poisson ratio. The method comprises the following steps: firstly, designing an intravascular stent original configuration with negative poisson ratio in radial and axial directions based on a negative poisson ratio structural unit; then, manufacturing additive of the biodegradable shape-memory polymer intravascular stent additive with a negative poisson ratio by adopting a micro-droplet jetting additive technology; and finally, testing the performance of the intravascular stent. According to the method, a complex geometric intravascular stent from micro-droplet jetting additive, so that the shape and performance controlling capacity of the intravascular stent can be effectively improved; minimal invasive implantation of the intravascular stent can be realized by utilizing the negative poisson ratio; in the stent expanding process, the vascular wall is uniformly stressed, so that injury can be effectively avoided, and stent migration is avoided due to no axial contraction; and the shape-memory spontaneous gradual expansion and biodegradability of the biodegradable shape-memory polymer intravascular stent can be realized under dynamic excitation, and the problems of in-stent restenosis, taking-out difficulty after implantation and the like can be effectively avoided.

Systems and methods are described for automatically identifying coronary stents within a 3D cardiac image. Based on feature analysis on a cardiac image, coronary stents can be detected by filtering the cardiac images for stent candidates, applying a score based on factors related to coronary stents and applying a threshold. Once coronary stents are identified, in-stent restenosis and stent fractures can be further detected.

The invention discloses a method for preparing a personalized bionic drug eluting coronary stent by using a 3D printing technology and a product. The method for preparing the personalized bionic drug eluting coronary stent comprises the step that according to image data of coronary angiogram, adopting a QCA technique for measuring the diameter of a diseased coronary artery and reconstructing in a three-dimensional manner. According to indexes such as lesion vascular diameter, lesion length and lesion vascular pattern, a personalized coronary stent can be made for each patient in a customized manner and a stent most suitable for the lesion state of a patient can be prepared. The personalized bionic drug eluting coronary stent can be made of degradable poly L-lactic acid (PLLA) or other materials, after 3D printing molding, the surface of the stent can be coated with a polymer with anti-proliferation medicines by using a conventional process, and in-stent restenosis can be reduced (the polymer is prepared by mixing a medicine with PDLLA in a ratio of the medicine to PDLLA being 1:1). The most suitable personalized bionic drug eluting coronary stent can be customized for the patient according to diseased coronary arteries of different states, requirements of different lesions can be met, customization of coronary stents can be achieved, and complications such as vascular injury, thrombus and coronary arterial dissection caused by mismatching of the diameter of the stent and that of the blood vessel can be reduced.

A catheter and catheter system can use energy tailored for remodeling and / or removal of target material proximate to a body lumen, often of stenotic material or tissue in the luminal wall of a blood vessel of a patient. An elongate flexible catheter body with a radially expandable structure may have a plurality of electrodes or other electrosurgical energy delivery surfaces to radially engage the luminal wall when the structure expands. Feedback using one or parameters of voltage, current, power, temperature, impedance magnitude, impedance phase angle, and frequency may be used to selectively control the delivery of energy.

The invention discloses application of salvianolic acid A in preparation of medicine for resisting tunica intima thickening, post-angioplasty restenosis and / or in-stent restenosis. Experimental research finds that salvianolic acid A can restrain proliferation of umbilical cord artery blood vessel smooth muscle cells of a person and reduce the tunica intima thickening rate and the blood vessel lumen restenosis rate of a tunica intima thickening animal model after balloon injury, has the remarkable effects of resisting tunica intima thickening and post-angioplasty restenosis and / or in-stent restenosis, can be used for preparing the medicine for restraining tunica intima thickening, post-angioplasty restenosis and / or in-stent restenosis and is particularly used for preparing medicine for preventing post-percutaneous coronary angioplasty restenosis and in-stent restenosis or used for preparing a drug eluting stent. In this way, efficient, safe and economical prevention and treatment medicine and an efficient, safe and economical solution are provided for prevention and treatment of post-angioplasty, particularly post-percutaneous coronary angioplasty restenosis and in-stent restenosis.

The invention relates to an intracranial drug eluting stent system and a preparation method thereof, in particular to an intracranial drug eluting stent used for treating the intracranial atherosclerotic stenosis disease .The intracranial drug eluting stent is composed of a metal stent body and a coating structure covering the surface of the metal stent body, the coating structure comprises one or more stent substrate coatings and drug coatings, and the drug coatings contain a biodegradable drug carrier and a drug inhibiting excessive proliferation of VSMCs .According to the intracranial drug eluting stent, the diseased artery is expanded with the stent to improve intracranial artery blood perfusion, the drug carried by the stent can prevent excessive proliferation of endangium, and thus the probability of in-stent restenosis is lowered; meanwhile, stent healing in the artery can be rapidly achieved, and thus long-term safety and effectiveness are ensured for patients.

The invention discloses a degradable vascular stent structure with a negative Poisson ratio to make up defects of design of degradable vascular stents in the prior art and belongs to the field of medical equipment. The vascular stent structure is formed by arranging concave hexagonal base structure units in the annular and axial directions of a stent and is made of a degradable material. The vascular stent structure is designed on the specificity of the degradable material and has a negative Poisson ratio effect. A degradable vascular stent with the structure can be matched with the negative Poisson ratio effect of tunica intima tissue after being implanted into blood vessels, so that injury caused by the stent to vascular tissue and the probability of in-stent restenosis are reduced, thestent can be completely degraded in vivo finally, and degradation products of the stent are absorbed and metabolized by the human body.

The invention discloses a nano multi-coating medicine stent and a preparation method thereof. A stainless steel metal stent is covered by a nano ceramic coating, wherein an REDV (Arg-Glu-Asp-Val) mono-molecule layer is covered outside the nano ceramic coating; a PLGA (Polylactic-co-Glycolic Acid)-rapamycin coating is covered outside the REDV mono-molecule layer. The preparation method of the nano multi-coating medicine stent comprises the following steps: 1) manufacturing the stainless steel metal stent; 2) preparing a TiO2 coating; 3) forming a polydopamine film on the TiO2 coating; 4) creating the REDV mono-molecule layer on the surface of the polydopamine film; 5) preparing a PLGA-RAPA (Rapamycin) solution; 6) forming a medicine coating. The nano multi-coating medicine stent and the preparation method thereof have the advantages of further reducing occurrence rate of in-stent restenosis after a stent implanting operation, suppressing proliferation of smooth muscle cells, accelerating vascular endothelium process, reducing hemorrhage risk caused due to long-term antithrombotic therapy, reducing medical cost of operators and being significant in economic and social benefits.

The invention provides a peripheral drug eluting stent. A drug coating of the peripheral drug eluting stent is divided into an outer sustained-release layer, an intermediate drug sustained-release mixed layer and an inner drug sustained-release mixed layer. The outer sustained-release layer is PLGA with molecular weight being 30000, and PLA:PGA=70:30. The intermediate drug sustained-release mixed layer is a mixture of PTX and PLGA, wherein the molecular weight of PLGA is 20000, PLA:PGA=50:50, and the mass ratio of PTX to PLGA is 3:1. The inner drug sustained-release mixed layer is a mixture of PTX and PLGA, wherein the molecular weight of PLGA is 20000, PLA:PGA=80:20, and the mass ratio of PTX to PLGA is 3:1. The invention further relates to preparation and application of the peripheral drug eluting stent. The peripheral drug eluting stent can effectively treat peripheral artery stenosis, and the problem of in-stent restenosis after a traditional peripheral bare metal stent is implanted into the peripheral vessel is avoided.

The invention relates to a bidirectional double-drug eluting stent and a preparation method thereof. The bidirectional double-drug eluting stent is used for carrying out percutaneous coronary intervention operations so as to supply expansion support to heart and blood vessels of a patient. An A drug layer containing a drug capable of inhibiting the proliferation of smooth muscles is applied to theouter side surface, namely the surface in contact with an inner surface of a blood vessel after mounting, of the stent; and a B drug layer containing a drug capable of accelerating the reendothelialization of the blood vessel and stabilizing or reversing plaques is applied to the side surface, namely the surface deviated from the inner surface of the blood vessel after mounting, of the stent. According to the bidirectional double-drug eluting stent, the cell proliferation of the smooth muscles can be inhibited, so that the in-stent restenosis and the rapid endothelialization are inhibited, the plaques can be stabilized and reversed, the new atherosclerosis is prevented, and the occurring risk of later-period thrombus is reduced.

The invention discloses a Chinese herbal medicine preparation for curing angina pectoris, myocardial infarction and preventing in-stent restenosis, which is developed by a cardiovascular disease curing expert and President Shang Xiaoming through the understanding of the pathogenesis of chest stuffiness based on traditional Chinese medical science and the combination of modern pharmacological knowledge. The Chinese herbal medicine preparation comprises the following active pharmaceutical ingredients: danshen root, astragalus, red peony root, angelica sinensis, rhizomaligusticichuanxiong, peach kernel, safflower, hirudo, earth worm and rhizoma pinelliae. The drug is compatible with the dialectic theory of Chinese traditional medicine, which has multiple effects of activating blood circulation to dissipate blood stasis, improving blood circulation, nourishing pneuma and benefiting marrow, soothing nerves and promoting intelligence, can expand peripheral vascular, and improve microcirculation, and can prolong the aggregation time of fibrinogen remarkably and inhibit myocardial fibrosis effectively. Thereby, the Chinese herbal medicine preparation has the advantages of low price, good efficacy, no poison and side effect, and broad market prospects.

The invention provides an anti-skid, self-dilating and degradable esophagus stent with a negative Poisson's ratio structure. The anti-skid, self-dilating and degradable esophagus stent with the negative Poisson's ratio structure is characterized by comprising a main stent body made of a totally or partially degradable material, wherein the main stent body comprises an upper end part, a middle partand a lower end part which are connected in sequence, an upper port and a lower port are formed in the top end of the upper end part and the bottom end of the lower end part respectively, and inner diameter of the upper port and inner diameter of the lower port are both larger than inner diameter of the middle part. Minimally invasive implanting of the esophagus stent is realized by the negativePoisson's ratio effect, and the esophagus wall is uniformly stressed in the stent dilating process, so that damage is effectively prevented, axial shrinkage is avoided and the stent is prevented fromdisplacing; meanwhile, by means of the negative Poisson's ratio structure, discomfort of a patient in an eating process can be relieved by the radial process of the stent while displacement is avoidedin the eating and swallowing process of the patient. The esophagus stent dilates automatically and gradually and is biodegradable under external motivation, and the problems of in-stent restenosis, difficulty in taking-out after implantation and the like are effectively solved.

The invention discloses a medicament for preventing in-stent restenosis after coronary stent implantation and a preparation method. The medicament is prepared into 1000 parts from, by weight, 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of camphol and borneol and 6-9 parts of musk ketone. The medicament has the advantages of effective treatment, no toxic and side effects and capabilities of decreasing occurrence rate of in-stent restenosis after coronary stent implantation, obviously improving clinical symptoms of patients and reducing long-term risks of thrombosis of the patients, and is obvious in clinical effect. The medicament provides a new choice for preventing ISR (in-stent restenosis) after coronary stent implantation.

The invention discloses an encephalic drug eluting stent in the field of medicines, and particularly relates to the drug eluting stent used for curing the encephalic atherosclerotic stenosis disease. Diseased blood vessels are expanded by the stent to improve the condition of stenosis, so as to improve the blood flow state, meanwhile, drug carried by the stent can be used for preventing a tunica elastica interna from hyperplasia, and the probability of in-stent restenosis can be lowered. The encephalic drug eluting stent comprises a conveying system, a stent body and a stent drug carrying layer, and is characterized in that one or more drug carrying layers are attached to the surface of the encephalic drug eluting stent; each drug carrying layer is composed of a polymer and an active ingredient, the active ingredient is an antiplatelet drug cilostazol, and each drug carrying layer comprises the following components by weight percent: 5 to 50 percent of the polymer and the balance of active ingredients; the active ingredients in all medicine carrying layers are the same or different. The encephalic drug eluting stent provided by the invention has the advantages that the functions of protecting blood vessels, restraining inflammation reactions, expanding blood vessels and the like can be achieved, and the purpose of preventing encephalic vascular in-stent restenosis can be achieved.

The invention belongs to the technical field of biomedicine and medical materials, and relates to a beta-elemene controlled-release eluting stent for preventing and treating coronary artery in-stent restenosis. The medicine stent takes a stent as a medicine carrying tool, the effective medicine ingredient beta-elemene achieves controlled releasing through a coating, and the in-stent restenosis is prevented and treated by inhibiting smooth muscle cell proliferation and inducing cell apoptosis; meanwhile, in-stent late thrombosis is prevented by protecting endothelial cells against damage and inhibiting the thrombosis effect. According to the medicine controlled-release eluting stent, in-vitro controlled-release test results show that more than half of the medicine is still not released after six months, the releasing time is significantly prolonged compared with a homologous pure polymer, and the sustained action of the medicine is guaranteed; animal experiments prove that the beta-elemene controlled-release eluting stent can effectively prevent and control the coronary artery in-stent restenosis and thrombosis and has the safety and feasibility.

The invention discloses an application of immune regulation markers TIPE2 (Tumor Necrosis Factor-a Induced Protein 8 like 2) in preparation of a medicine used for treating vascular proliferation diseases, and also discloses a recombinant adenovirus for expressing the TIPE2. The recombinant adenovirus for the TIPE2 is adopted to realize the in-vivo continuous high expression of TIPE2 protein, which shows the function on inhibiting excess proliferation of a vascular smooth muscle cell, inhibits the hyperplasia of neointima caused by the vascular injury in order to reduce vascular stenting postoperative complication and prognosis and other postoperative complications and prognoses, creates a new path with a wide prospect on effectively preventing and treating the vascular in-stent restenosis of acute coronary syndrome and intervening other vascular proliferation diseases on the cytological basis of vascular smooth muscle proliferation in clinic, and also provides the reference for developing a novel medicine.

The present invention relates to new use of inhibitors of bcl-2 / bcl-XI family of anti-apoptotic compounds for the treatment of post-angioplasty restenosis and in-stent restenosis. Small molecules of Bcl inhibitors are incorporated into a stent, typically by a fine polymeric coating over the metal, which would be placed during angioplasty of occluded blood vessels, to act on fibroproliferative in-growth. Hollow organs such as urethras, Fallopian tubes and vascular access grafts could be treated in a similar manner to prevent their closure due to fibrosis. Other iatrogenic fibrosis such as adhesions after surgery could also be blocked by this therapy.

The invention aims at providing a PLGA-S1P nanometer material and a preparation method of a PLGA-S1P nanometer coating stent. The preparation method is characterized by comprising the following steps that S1P is subjected to PLGA coating by a solvent emulsifying method by using an ultrasonic dispersion method, and the ratio of the S1P to PLGA is 1:(10 to 200) (w / w); then, an organic solvent is removed by a method of diffusing an emulsifying agent to water; and finally, freeze-dried powder is prepared by using a freeze-drying concentration method. The PLGA-S1P nanometer particle freeze-dried powder is added into the solvent; after the ultrasonic dissolution, the solution is used as a medicine carrying coating solution; a stainless steel stent is cleanly cleaned; the medicine carrying coating solution is repeatedly sprayed and coated on the surface of the stent by a high-voltage electric spinning method / an ultrasonic spray coating technology; the coating thickness is controlled to be 5 to 20 <mu>m; a de-ionized water / organic solvent volatilization method is used for cleaning; and the PLGA-S1P nanometer coating stent is obtained after the sterilization. The PLGA-S1P nanometer particles are used as the surface coating material of a metal bare stent; and the goal of inhibiting the in-stent restenosis can be achieved. The invention provides a novel method for the interventional therapy for preventing arteriostenosis / occlusion diseases.

The invention discloses a medicine for preventing restenosis after the intracoronary stent implantation, which is characterized by comprising the components in parts by mass as follows: 200-250 parts of astragalus mongholicus, 35-50 parts of ginseng, 65-85 parts of radix ophiopogonis, 220-245 parts of salvia miltiorrhiza, 65-90 parts of lignum dalbergiae odoriferae, 100-130 parts of fructus aurantii, 100-125 parts of ligusticum wallichii, 105-130 parts of poria cocos, 65-90 parts of processed rhizoma pinelliae, 105-135 parts of trichosanthes kirilowii maxim, 85-105 parts of allium macrostemon, 105-138 parts of pericarpium citri reticulatae and 60-85 parts of liquorice. Compared with the prior art, the medicine can prevent a restenosis phenomenon after the intracoronary stent implantation, effectively relieve angina, and prevent and treat in-stent restenosis.

Provided herein are methods of treating postangiplasty, in-stent restenosis or atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone with or with a effective dose of one or more of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. Also provided are pharmaceutical compositions comprising a morelloflavone or pharmaceutical combinations comprising a morelloflavone and one of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent.